Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply

Aliment Pharmacol Ther. 2023 Mar;57(6):743-744. doi: 10.1111/apt.17407.

Authors

Adriaan Volkers¹, Tessa Straatmijer^{1

2}, Marjolijn Duijvestein³, Mark Löwenberg¹, Andrea van der Meulen², Geert D'Haens¹

Affiliations

¹ Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
² Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, the Netherlands.
³ Department of Gastroenterology, Radboud University Medical Center, Nijmegen, the Netherlands.

PMID: 36821751
DOI: 10.1111/apt.17407

No abstract available

Publication types

Letter
Comment

MeSH terms

Administration, Intravenous
Antibodies, Monoclonal, Humanized
Humans
Inflammatory Bowel Diseases*

Substances

vedolizumab
Antibodies, Monoclonal, Humanized